Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2022 02:00 ET | Source: Immunicum AB

Immunicum to Participate in Upcoming Investor and Industry Conferences in January

Press Release Stockholm, Sweden, January 3, 2022 Immunicum to Participate in Upcoming Investor and Industry Conferences in January Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical...
December 21, 2021 02:00 ET | Source: Immunicum AB

Immunicums VD sammanfattar året och tillkännager kommande aktieägarevent för att presentera strategi för klinisk pipeline

Pressmeddelande Stockholm, 21 december, 2021 Immunicums VD sammanfattar året och tillkännager kommande aktieägarevent för att presentera strategi för klinisk pipeline Immunicum AB (“Immunicum”...
December 21, 2021 02:00 ET | Source: Immunicum AB

Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook

Press Release Stockholm, Sweden, December 21, 2021 Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook Immunicum AB (“Immunicum” publ;...
December 11, 2021 09:00 ET | Source: Immunicum AB

Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021

Pressmeddelande Stockholm, 11 december, 2021 Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021 Immunicum AB...
December 11, 2021 09:00 ET | Source: Immunicum AB

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB...
December 03, 2021 02:00 ET | Source: Immunicum AB

Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studien

Pressmeddelande 3 december 2021 Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studienImmunicum AB (“Immunicum”, publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på...
December 03, 2021 02:00 ET | Source: Immunicum AB

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Press Release Stockholm, Sweden, December 3, 2021 Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical...
November 30, 2021 02:00 ET | Source: Immunicum AB

Immunicum och PCI Biotech tillkännager förlängning av sitt forskningssamarbete med att utforska nya behandlingar med cancervaccin

Pressmeddelande Stockholm 30 november, 2021 Immunicum och PCI Biotech tillkännager förlängning av sitt forskningssamarbete med att utforska nya behandlingar med cancervaccin Immunicum AB...
November 30, 2021 02:00 ET | Source: Immunicum AB

Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments

Press Release Stockholm, Sweden, November 30, 2021 Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments Immunicum AB (publ;...
November 30, 2021 02:00 ET | Source: PCI Biotech Holding ASA

PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments

Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and...